Durable and Deepening Clinical Responses Observed in Post-Treatment Period of Evelo Bioscience’s Phase II Clinical Trial of Oral EDP1815 in Psoriasis

Evelo Biosciences, Inc. announced data from the post-treatment follow-up of its Phase II trial of EDP1815 in mild and moderate psoriasis including durable and deeper clinical responses.